Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule.
about
Detailed analysis of the variability of peptidylarginine deiminase type 4 in German patients with rheumatoid arthritis: a case-control studyRheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentinCitrullination of proteins: a common posttranslational modification pathway induced by different nanoparticles in vitro and in vivoChromogranin A is an autoantigen in type 1 diabetesCarbamylation-dependent activation of T cells: a novel mechanism in the pathogenesis of autoimmune arthritisCitrullination, a possible functional link between susceptibility genes and rheumatoid arthritisAutoantibodies in normals--the value of predicting rheumatoid arthritisCitrullinated proteins: sparks that may ignite the fire in rheumatoid arthritisA combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritisAntibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritisDoes a positive anti-CCP test identify a distinct arthritis entity?Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severityThe Autoimmune EcologyRheumatoid Arthritis: The Stride from Research to Clinical PracticeRecent advances in understanding Type 1 DiabetesGenetic studies of rheumatoid arthritisT cell epitopes and post-translationally modified epitopes in type 1 diabetesUp-to-Date Information on Rheumatoid Arthritis-Associated Interstitial Lung DiseasePathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLEThe effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responsesThe lung in ACPA-positive rheumatoid arthritis: an initiating site of injury?Citrullination-dependent differential presentation of a self-peptide by HLA-B27 subtypesStructure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritisSynthesis and Screening of a Haloacetamidine Containing Library To Identify PAD4 Selective InhibitorsA molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritisRegulation of B lymphocytes and plasma cells by innate immune mechanisms and stromal cells in rheumatoid arthritis.Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritisAire-ing self antigen variability and toleranceEmerging patterns of risk factor make-up enable subclassification of rheumatoid arthritisGenetics and epigenetics of rheumatoid arthritisNitration of the pollen allergen bet v 1.0101 enhances the presentation of bet v 1-derived peptides by HLA-DR on human dendritic cellsAssociation of levels of antibodies against citrullinated cyclic peptides and citrullinated α-enolase in chronic and aggressive periodontitis as a risk factor of Rheumatoid arthritis: a case control study.Immune recognition of citrullinated epitopes.Synovial detection and autoantibody reactivity of processed citrullinated isoforms of vimentin in inflammatory arthritides.Comorbidities of rheumatoid arthritis: Results from the Korean National Health and Nutrition Examination Survey.Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodiesRoles of B cells in rheumatoid arthritisPorphyromonas gingivalis and the pathogenesis of rheumatoid arthritis: analysis of various compartments including the synovial tissue.Gene-gene and gene-environment interactions in ulcerative colitis.Synovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritis.
P2860
Q21195665-F034DB72-B4E9-413A-90BB-3F22F1709E33Q21195679-BD269AFE-DE6A-41A6-A94E-E8EE8687505EQ23910338-995329F8-6C3F-4547-95E8-94507348B3F1Q24605199-D182FB9D-F103-426E-8A11-518CB7314889Q24629328-987A8767-74F0-49E5-8872-6B3B8A57E05CQ24793137-31E85BC1-B237-437C-82BD-3F5BE1D95E11Q24798609-A2E1EDE7-B307-4B1D-8FF4-6B20797502C2Q24801080-E9945F31-E931-40D9-B2E4-1D22BCDDB50FQ24805387-288447C7-039B-4003-8886-BED9776194A1Q24812184-2E91ECD8-F695-4A81-8FEE-2456F90DA7ECQ24812995-B1C844FA-5A05-4DE5-B968-9FAD1A7B13A6Q24816615-1244200A-7DAC-4876-BFAE-CFD1D6E6A7F2Q26747427-4F32E3F2-FCAE-4B72-B500-86B15B85B92DQ26747512-6008A19C-5082-40A9-B7AC-AA66C05523D6Q26766139-0583319A-33E6-4B93-924B-10DCBE56B0E6Q26783892-D4F3E50E-0A48-4468-A128-3A339D38B418Q26787014-90F5B7D8-D507-4B7C-820A-2165AAB57F87Q26825098-1D45461A-64F4-45EB-A86F-B5B721DA28D0Q27003201-52222747-9988-4FA4-A707-3ECA19420B87Q27022645-EFE348E9-F39E-4790-AC5F-5E88F94EAA47Q27023243-BB1E8B4A-E8BF-4FB0-82F0-FB8B0D9515D7Q27651301-140C44C5-9AA2-4CEE-BB3F-D6F8BDAFE335Q27653688-8EE36125-5FBE-44A5-9372-22F3DE69B180Q27675108-4C6AF269-F1B2-4FE8-8AD0-334763519938Q27680522-C6AD4811-2C27-4C43-AC6A-558A7E6D4DA7Q27686770-82A5E0BA-85A3-440E-8E42-F9DAB92DDEB6Q28238667-5ABFECF6-04E4-4648-99EC-3749BAA7F7C6Q28290220-7AF8AD01-ADD9-4588-88D1-281BF5D7C46EQ28304210-EC6C7458-6C80-4279-A939-3F6915D3EE0FQ28534348-5DA2C4CA-C01F-4C74-91A6-0F626DB1F7A3Q28732106-25188DF2-8ABB-4177-BF4D-ADCDC88A5ECFQ30316226-12A08309-2FC4-4504-A17D-3C5D0DB5DDFEQ30391892-1E894F1A-B6A2-47E5-A951-93D488C29BE2Q33322989-7222A2DC-A973-44B8-8B69-DF3F9B4217F2Q33579891-4972C937-950A-4491-AA58-2B64B5433DC9Q33673310-5A697195-041F-43AE-B7F5-818F25D12F7DQ33708839-FA0DA5E3-5548-43F4-BC30-69DE4544F1E8Q33766304-A13CF2E7-CAF6-41EE-AB0D-C81F85746ABAQ33781693-70B24394-7E11-49B2-B9A7-5302C7C3F442Q33822112-73AA3F8B-67BF-4E74-85B0-821B59B4B146
P2860
Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Cutting edge: the conversion o ...... B1*0401 MHC class II molecule.
@en
Cutting edge: the conversion o ...... B1*0401 MHC class II molecule.
@nl
type
label
Cutting edge: the conversion o ...... B1*0401 MHC class II molecule.
@en
Cutting edge: the conversion o ...... B1*0401 MHC class II molecule.
@nl
prefLabel
Cutting edge: the conversion o ...... B1*0401 MHC class II molecule.
@en
Cutting edge: the conversion o ...... B1*0401 MHC class II molecule.
@nl
P2093
P1476
Cutting edge: the conversion o ...... B1*0401 MHC class II molecule.
@en
P2093
Anthony M Jevnikar
David A Bell
Ewa Cairns
Jonathan A Hill
Scott Southwood
P304
P356
10.4049/JIMMUNOL.171.2.538
P407
P577
2003-07-01T00:00:00Z